Trabalho de evento-resumo periodico

Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) (2021)

• Authors:
  • Bonifacio, L.
  • Ramacciotti, E.
  • Agati, L.
  • Vilar, F.
  • Tojal, A.
  • Souza, H.
  • Louzada Júnior, Paulo
  • Fonseca, Benedito Antonio Lopes da
  • Lopes, R.
  • Kallas, Esper Georges
  • Bellíssimo-Rodrigues, Fernando
• USP affiliated authors: LOUZADA JÚNIOR, PAULO - FMRP ; FONSECA, BENEDITO ANTONIO LOPES DA - FMRP ; KALLAS, ESPER GEORGES - FM ; RODRIGUES, FERNANDO BELLISSIMO - FMRP
• Unidades: FMRP; FM
• Subjects: COVID-19; PACIENTES INTERNADOS; ESTUDOS MULTICÊNTRICOS; ESTUDOS PROSPECTIVOS; CITOCINAS; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
• Agências de fomento:
  • Financiamento MCTI
  • Financiamento CNPq
• Language: Inglês
• Imprenta:
  • Publisher place: London
  • Date published: 2021
• Source:
  • Título: Antimicrobial Resistance & Infection Control
  • ISSN: 2047-2994
  • Volume/Número/Paginação/Ano: v. 10, suppl. 1, p. 61, res. P107, 2021
• Conference titles: International Conference on Prevention & Infection Control (ICPIC 2021)


---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  BONIFACIO, L. et al. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf. Acesso em: 30 dez. 2025. , 2021

• APA

  Bonifacio, L., Ramacciotti, E., Agati, L., Vilar, F., Tojal, A., Souza, H., et al. (2021). Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf

• NLM

  Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 dez. 30 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf

• Vancouver

  Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 dez. 30 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
• Bacillary angiomatosis in a pregnant woman
• Manifestação extrapulmonar da tuberculose apresentando-se como pseudotumor orbitário
• Lower numbers of natural killer T cells in HIV-1 and mycobacterium leprae co-infected patients
• No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis
• Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
• HLA-C downregulation by HIV-1 adapts to host HLA genotype
• Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance
• Antigenic competition in CD4(+) T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial
• Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial